Evidence map›Paper›PMID 41790186›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Distance-based evaluation of tumor budding in colorectal cancer.

Ville K Äijälä, Päivi Sirniö, Henna Karjalainen, Meeri Kastinen, Vilja V Tapiainen, Hanna Elomaa, Maarit Ahtiainen, Vesa-Matti Pohjanen, Taneli T Mattila, Outi Lindgren and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ville K ÄijäläTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Päivi SirniöTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Henna KarjalainenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Meeri KastinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Vilja V TapiainenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Hanna ElomaaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Maarit AhtiainenCentral Finland Biobank, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
Vesa-Matti PohjanenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Taneli T MattilaTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Outi LindgrenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Olli HelminenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Erkki-Ville WirtaDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
Jukka RintalaTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Sanna MeriläinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Juha SaarnioTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Tero RautioTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Toni T SeppäläDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
Jan BöhmDepartment of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.
Jukka-Pekka MecklinDepartment of Education and Research, Well Being Services County of Central Finland, Jyväskylä, Finland.
Anne TuomistoTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Markus J MäkinenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Juha P VäyrynenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland. juha.vayrynen@oulu.fi.ORCID http://orcid.org/0000-0002-8683-2996

Funding

Finnish State Research Funding through Pirkanmaa welfare area T66854Finnish State Research Funding through Pirkanmaa welfare area T67954Mary och Georg C. Ehrnrooths Stiftelse 202400018Sigrid Juséliuksen Säätiö 230229Sigrid Juséliuksen Säätiö 240194Sigrid Juséliuksen Säätiö 240241Sigrid Juséliuksen Säätiö 250264Suomen Lääketieteen Säätiö 6021Syöpäsäätiö 59-5619Syöpäsäätiö 63-6409Syöpäsäätiö 69-7354
6 · The paper itself

Abstract

Tumor budding is an established adverse prognostic factor in colorectal cancer (CRC), based on the number of isolated single tumor cells or small tumor cell clusters at the invasive front. While bud counts are well studied, the prognostic significance of the spatial distribution and distance of tumor buds away from the tumor bulk is unclear. We defined TB-distance as the average distance from the tumor bulk to the three farthest tumor buds and evaluated its clinicopathologic and prognostic associations in two independent CRC cohorts (N = 776 and N = 1,100). Using a cohort-derived cutoff, high TB-distance (≥ 123 µm) was significantly associated with adverse tumor characteristics, including high grade, advanced disease stage, lymphovascular invasion, high conventional tumor budding grade, and MMR proficient status (p < 0.003 for all). High TB-distance was also associated with shorter cancer-specific survival (Cohort 1: multivariable HR (high vs. low) 1.47, 95% CI 1.04-2.09, p = 0.030; Cohort 2: multivariable HR 1.34 95% CI 1.04-1.74, p = 0.026). However, TB-distance did not provide additional prognostic information within conventional tumor budding grade strata or when modeled alongside tumor budding. These findings indicate that high TB-distance is associated with aggressive tumor morphology and worse outcome but does not improve prognostication beyond standard tumor budding assessment. TB-distance may still be useful as a visual aid in routine pathology and a quantifiable spatial feature for computational pathology.

Indexed as

CohortColorectal cancerPrognosisTumor budding

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.